This study is in progress, not accepting new patients
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Aerovate Therapeutics
- ID
- NCT05036135
- Phase
- Phase 2/3 research study
- Study Type
- Interventional
- Participants
- Expecting 462 study participants
- Last Updated